203 related articles for article (PubMed ID: 35696112)
1. A rapid strategy for screening high-efficiency PCSK9 inhibitors from Ginkgo biloba leaves by ligand fishing, HPLC-Q-TOF-MS and interdisciplinary assay.
Li L; Fan ML; Li YN; Huang YX; Liu XF; Liu JH
J Food Drug Anal; 2020 Jun; 28(2):273-282. PubMed ID: 35696112
[TBL] [Abstract][Full Text] [Related]
2. Rapid screening and identification of monoamine oxidase-A inhibitors from Corydalis Rhizome using enzyme-immobilized magnetic beads based method.
Zhang Y; Wang Q; Liu R; Zhou H; Crommen J; Moaddel R; Jiang Z; Zhang T
J Chromatogr A; 2019 May; 1592():1-8. PubMed ID: 30712820
[TBL] [Abstract][Full Text] [Related]
3. Immobilized α-amylase magnetic beads for ligand fishing: Proof of concept and identification of α-amylase inhibitors in Ginkgo biloba.
Petersen MJ; de Cássia Lemos Lima R; Kjaerulff L; Staerk D
Phytochemistry; 2019 Aug; 164():94-101. PubMed ID: 31103779
[TBL] [Abstract][Full Text] [Related]
4. A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro.
Li L; Shen C; Huang YX; Li YN; Liu XF; Liu XM; Liu JH
Molecules; 2018 Sep; 23(9):. PubMed ID: 30235833
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
6. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
Shen L; Peng H; Xu D; Zhao S
Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
[TBL] [Abstract][Full Text] [Related]
7. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
Shimada YJ; Cannon CP
Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287
[TBL] [Abstract][Full Text] [Related]
9. Proprotein convertase subtilisin/kexin type 9 inhibitor utilization and low-density lipoprotein-cholesterol control in familial hypercholesterolemia.
Jackson CL; Deng Y; Yao X; Van Houten H; Shah ND; Kopecky S
J Clin Lipidol; 2021; 15(2):339-346. PubMed ID: 33419720
[TBL] [Abstract][Full Text] [Related]
10. Combined magnetic ligand fishing and high-resolution inhibition profiling for identification of α-glucosidase inhibitory ligands: A new screening approach based on complementary inhibition and affinity profiles.
Wubshet SG; Liu B; Kongstad KT; Böcker U; Petersen MJ; Li T; Wang J; Staerk D
Talanta; 2019 Aug; 200():279-287. PubMed ID: 31036185
[TBL] [Abstract][Full Text] [Related]
11. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
12. Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse.
Saeed A; Virani SS; Jones PH; Ballantyne CM; Nambi V
J Clin Lipidol; 2018; 12(5):1141-1145. PubMed ID: 30318064
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
[TBL] [Abstract][Full Text] [Related]
14. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and LDL lowering in the contemporary management of dyslipidemia.
Switzer MP; Nwosu AC; Juan ZS; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):281-8. PubMed ID: 24164109
[TBL] [Abstract][Full Text] [Related]
15. A strategy for screening of α-glucosidase inhibitors from Morus alba root bark based on the ligand fishing combined with high-performance liquid chromatography mass spectrometer and molecular docking.
Wang Z; Li X; Chen M; Liu F; Han C; Kong L; Luo J
Talanta; 2018 Apr; 180():337-345. PubMed ID: 29332820
[TBL] [Abstract][Full Text] [Related]
16. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Ling H; Burns TL; Hilleman DE
Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
[TBL] [Abstract][Full Text] [Related]
17. Immobilized fusion protein affinity chromatography combined with HPLC-ESI-Q-TOF-MS/MS for rapid screening of PPARγ ligands from natural products.
Zhu J; Yi X; Liu W; Xu Y; Chen S; Wu Y
Talanta; 2017 Apr; 165():508-515. PubMed ID: 28153290
[TBL] [Abstract][Full Text] [Related]
18. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
19. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
[TBL] [Abstract][Full Text] [Related]
20. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
